Daily Bio News Summary — 2026-09-23

Wednesday’s harvest produced twenty-one news items across six sources: Endpoints News (6), BioSpace (6), PR Newswire’s FDA feed (4), Fierce Pharma (3) and Fierce Biotech (2). Clinical readouts dominated the immunology and kidney spaces, two AI-native discovery companies raised a combined $451 million, and the day carried a steady background hum of workforce and manufacturing news on both sides of the Atlantic.

The FcRn story turns: one asset, two readings

The most consequential clinical result of the day was Immunovant’s decision to stop developing IMVT-1402 in cutaneous lupus erythematosus after a midphase test failed to separate from placebo on a disease area and severity score at week 12 (Endpoints News, 2026-09-23). Endpoints frames the readout as a blow to parent-company Roivant, which counts the anti-FcRn antibody among its leading autoimmune pipeline candidates; Immunovant reportedly pointed to numerical trends and a relationship between deeper IgG reductions and response as partial silver linings.

That is the same axis on which the whole anti-FcRn field is being judged. Cutting an indication is not the same as invalidating the mechanism — deeper IgG knockdown correlating with response is precisely the hypothesis these programs are built on — but it does narrow the number of shots on goal for a class where several developers are pursuing nearly identical biology.

Celldex supplied the day’s second safety-versus-efficacy split: barzolvolimab hit its primary endpoint in two phase 3 trials in chronic hives, but the readout also raised safety concerns, and the stock fell (Endpoints News, 2026-09-23). A phase 3 win that the market treats as a loss is a reminder that in immunology, tolerability is now part of the efficacy story.

Roche moves on a crowded kidney market

Roche’s phase 3 win for its kidney drug sets up a path to accelerated approval, positioning the company to enter a market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved products (Endpoints News, 2026-09-23). Kidney disease has become one of the more reliably crowded competitive arenas in biopharma over the past two years, and a late entrant with a differentiated mechanism and an accelerated-approval route is a materially different proposition from a late entrant without one.

Obesity keeps compounding — and so does the capital

Three items kept the metabolic space moving:

• Viking Therapeutics reported that patients switched to a once-a-month dosing regimen of its obesity drug did not regain much weight after 12 weeks (Endpoints News, 2026-09-23) — a maintenance-endpoint datapoint of the kind that increasingly matters as the market looks past induction to durability.
• Eli Lilly presented early-stage data at Psych Congress 2026 supporting the potential of its next-generation GLP-1 and GIP receptor agonists in depression and alcohol use disorder (BioSpace, 2026-09-22), extending the incretin story well beyond weight and glycemia.
• Enveda — the AI drug hunter working on an “exercise in a tablet” oral obesity candidate — raised $311 million in a Series E crossover round to push three medicines into late-stage development, bringing its total raised to about $845 million in six years (BioSpace, 2026-09-23).

Lilly’s data is the one to watch: incretin receptors sit throughout the brain and body, and a credible neuropsychiatric signal would widen the addressable market in a way that no amount of obesity-market share can.

AI-native discovery takes its Series C and Series E

Alongside Enveda’s raise, London-based Basecamp Research closed a $140 million Series C at a valuation near $1 billion, unveiling a six-program pipeline guided by its EDEN model and spanning CAR-T and a PKU therapy (Endpoints News, 2026-09-23). Between the two rounds, roughly $450 million moved into AI-driven discovery in a single morning — capital that is increasingly being judged against named pipeline assets rather than model benchmarks.

Dealmaking tilts toward Asia and toward AI-designed targets

• Novartis exclusively licensed a preclinical radioligand therapy from Suzhou-based BoomRay Pharmaceuticals in a deal worth up to $900 million (BioSpace, 2026-09-23), deepening the company’s position in radiopharma, where it already markets Pluvicto and Lutathera.
• Boehringer Ingelheim expanded its collaboration with Variant Bio into cardiovascular disease, adding up to $250 million on top of a January pact originally worth $120 million (Fierce Biotech, 2026-09-23).
• GSK executives described a deliberate “balancing the West and the East” strategy that dates to its 2023 Hansoh Pharma deals, for which it paid a combined $270 million upfront for ex-China rights to two antibody-drug conjugates (Fierce Biotech, 2026-09-23).

The common thread is sourcing, not selling: three of the day’s larger transactions were about buying or licensing innovation from China or from AI platforms, rather than acquiring late-stage commercial assets.

Diagnostics, delivery and a regulatory green light

Three technical milestones landed outside the therapeutics mainstream:

• Werfen received both U.S. FDA 510(k) clearance and a CE mark for its Aptiva Antiphospholipid Syndrome IgA Reagent, completing the Aptiva APS portfolio (PR Newswire, 2026-09-23).
• Persista Bio reported positive FDA INTERACT feedback on its modular approach to an implantable, oxygenated cell therapy system for Type 1 diabetes — an attempt to remove the immunosuppression requirement that constrains cell therapy (PR Newswire, 2026-09-23).
• Sagent Pharmaceuticals launched Zyogreen, the first and only ready-to-use indocyanine green injection in the U.S., eliminating point-of-care reconstitution for fluorescence-guided procedures (PR Newswire, 2026-09-22).

Also worth noting: the FDA issued a warning letter to compounder Empower Pharmacy over its GLP-1 weight loss treatments — the third such warning for the Houston-based company (Endpoints News, 2026-09-23).

Workforce, Europe and the reshoring math

Bristol Myers Squibb plans another 265 layoffs tied to its Princeton, New Jersey headquarters, bringing its announced Garden State reductions this year past 700 (Fierce Pharma, 2026-09-22). The framing from BMS is consolidation around corporate functions rather than R&D, but the aggregate direction of large-pharma headcount remains down.

Meanwhile, BioSpace reported that pharma companies reshoring manufacturing are competing with each other — and with data centers — for a limited pool of qualified personnel (BioSpace, 2026-09-23), a tension that sits awkwardly beside a separate BioSpace item noting Pennsylvania biopharma job postings tripled year over year in August.

In Europe, the board chairs of nine prominent drugmakers warned that the bloc is “losing ground to global competition” on R&D, in a letter citing more than $600 billion of pharmaceutical investment mobilised by China and the U.S. over two years (Fierce Pharma, 2026-09-22). AstraZeneca, separately, recommitted to its UNICEF-partnered Young Health Programme, taking total investment in the initiative above $100 million (Fierce Pharma, 2026-09-23).

And in the less-obvious corner: Claros Technologies completed a commercial-scale pilot of its PFAS destruction system at Bachem’s Bubendorf, Switzerland campus, meeting the CDMO’s performance metrics for TFA as it expands into European pharmaceutical manufacturing (PR Newswire, 2026-09-22). Process-water contamination is a quiet but real constraint on pharma manufacturing footprints.

What this batch is NOT telling us

• No oncology readouts. Today’s clinical news was immunology, kidney and metabolic; a twenty-one-item batch with zero oncology data is unusual.
• No IPOs. Enveda’s Series E and Basecamp’s Series C are private rounds; the September IPO queue did not add a filing today.
• No megamerger. The day’s largest deal, Novartis-BoomRay at up to $900 million, is a licensing transaction, not an acquisition.
• No gene therapy pricing or launch news, despite the recent run of approvals in that space.
• No AI regulation or FDA policy items — the AI thread today was capital and pipeline, not oversight.

Reading order

1. Immunovant ends cutaneous lupus development (Endpoints News) — the day’s clearest clinical judgement call, and the one with the shortest path to consequences for the anti-FcRn class.
2. Roche’s phase 3 kidney win and the accelerated-approval path (Endpoints News) — competitive positioning in one of the most crowded late-stage markets.
3. Basecamp Research’s $140M Series C and six-program pipeline (Endpoints News) — the most specific disclosure of what an AI-native pipeline actually contains.
4. Viking’s once-a-month maintenance data (Endpoints News) — a dosing-durability datapoint in the highest-attention market in biopharma.
5. Nine European board chairs on R&D competitiveness (Fierce Pharma) — the policy framing that will shape where the next decade of capacity gets built.

How to read the underlying articles

Every item summarised here corresponds to a markdown file in src/content/news/. Each file carries a sourceUrl field pointing at the original reporting and a sourceName field identifying the outlet. Summaries are drawn strictly from harvested headline-and-deck metadata; figures such as deal values and endpoint language are quoted as the source reported them and are not independently verified by OpenBio News.

Items in this batch

1. Roche kidney drug’s Phase 3 win sets up path to accelerated approval — Endpoints News, 2026-09-23
2. AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push — BioSpace, 2026-09-23
3. Novartis bets up to $900M for radioligand therapy from China’s BoomRay — BioSpace, 2026-09-23
4. Roivant reports Phase 2b lupus failure for an FcRn drug — Endpoints News, 2026-09-23
5. Basecamp raises $140M Series C, unveils six-program pipeline in test of its AI — Endpoints News, 2026-09-23
6. Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials — Endpoints News, 2026-09-23
7. Viking touts once-a-month maintenance data for its weight loss candidate — Endpoints News, 2026-09-23
8. Compounder Empower receives FDA warning letter over GLP-1s — Endpoints News, 2026-09-23
9. Boehringer adds $250M to Variant pact via cardio expansion — Fierce Biotech, 2026-09-23
10. GSK aiming to ‘balance West and East’ since Hansoh deal success — Fierce Biotech, 2026-09-23
11. AstraZeneca recommits to youth health to dial funding past $100M — Fierce Pharma, 2026-09-23
12. BMS cuts another 265 jobs tied to New Jersey HQ — Fierce Pharma, 2026-09-22
13. European pharmas sound alarm over lagging innovation — Fierce Pharma, 2026-09-22
14. Lilly presents early data supporting GLP-1/GIP candidate’s potential in depression, alcohol use disorder — BioSpace, 2026-09-22
15. Pharmas face off for manufacturing talent amidst reshoring efforts — BioSpace, 2026-09-23
16. 9 companies hiring in Pennsylvania now — BioSpace, 2026-09-23
17. ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands — BioSpace, 2026-09-23
18. Persista Bio receives positive feedback on modular approach from FDA INTERACT — PR Newswire FDA, 2026-09-23
19. Werfen announces US FDA 510(k) clearance and CE mark for Aptiva antiphospholipid syndrome IgA reagent — PR Newswire FDA, 2026-09-23
20. Claros Technologies announces continued commercial expansion into Europe and entry into pharmaceutical manufacturing — PR Newswire FDA, 2026-09-22
21. Sagent Pharmaceuticals launches Zyogreen, the first and only ready-to-use indocyanine green injection in the U.S. — PR Newswire FDA, 2026-09-22